Contrary to conventional medical wisdom, metformin compares favorably with insulin for controlling blood sugar in A2 gestational diabetes—GD with elevated fasting blood sugar levels.
Contrary to conventional medical wisdom, metformin compares favorably with insulin for controlling blood sugar in A2 gestational diabetes-GD with elevated fasting blood sugar levels.
Researchers randomized women at less than 36 weeks' gestation to achieve normal blood sugar levels by either subcutaneous insulin injection (0.7 units) or 500 mg of metformin, with the goal of attaining postprandial blood glucose readings of less than 120 mg/dL and fasting blood sugars of between 60 and 90 mg/dL. Pregnant women were excluded from the study if they had conditions like insulin-dependent diabetes mellitus, chronic hypertension, or seizure disorders.
Thirty-one patients received insulin injection and 32 metformin. Those receiving the latter weighed about 30 lb more than the other group. Glucose levels were similar in each group and actually somewhat lower in the metformin group 2 hours after lunch (mean 106 vs. 112.5) and 2 hours after dinner (mean 108.1 vs. 109.2). There was little difference in abdominal delivery rates, shoulder dystocia, and postpartum hemorrhage and no differences in newborn statistics between the two groups, nor in birthweight, Apgar score at 5 minutes, or NICU admission.
The benefits of concurrent fetal and maternal heart rate monitoring
April 15th 2024A recent study revealed that employing maternal heart rate monitoring alongside fetal heart rate monitoring during labor significantly decreases the incidence of neonatal encephalopathy and severe neonatal acidemia.
Read More
How vitamin C intake in pregnant smokers impacts offspring airway function trajectory
April 12th 2024Investigating the impact of prenatal vitamin C supplementation on lung function and wheeze occurrence in offspring of pregnant smokers, revealing insights into mitigating respiratory risks.
Read More
NAID report shows maternal COVID-19 vaccination protects newborns
April 4th 2024New research led by the National Institute of Allergy and Infectious Diseases reveals sustained antibody levels in infants born to vaccinated mothers, underscoring the importance of maternal vaccination in safeguarding newborns against COVID-19.
Read More
FDA grants FTD to nipocalimab for treating FNAIT
March 26th 2024The FDA's Fast Track Designation for nipocalimab marks a significant step in addressing fetal neonatal alloimmune thrombocytopenia risk in pregnant patients, potentially revolutionizing treatment for this severe condition with unmet medical needs.
Read More